1stOncology™: Cancer Intelligence Service – Page 14398 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Pfenex Inc. to Present at Oppenheimer’s 28th Annual Healthcare Conference

On March 13, 2018 Pfenex Inc. (NYSE AMERICAN: PFNX), reported that the company will present at Oppenheimer’s 28th Annual Healthcare Conference in New York City (Press release, Pfenex, MAR 13, 2018, View Source2018-03-13-Pfenex-Inc-to-Present-at-Oppenheimers-28th-Annual-Healthcare-Conference" target="_blank" title="View Source2018-03-13-Pfenex-Inc-to-Present-at-Oppenheimers-28th-Annual-Healthcare-Conference" rel="nofollow">View Source [SID1234524737]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

President and Chief Executive Officer, Eef Schimmelpennink, is scheduled to present on Tuesday, March 20, 2018 from 4:30 PM – 5:00 PM ET in the Track 2 room.

Interested parties can access the live audio webcast for this presentation from the Investors Section of Pfenex’s website at www.pfenex.com. The webcast replay will be available after the conclusion of the live presentation for approximately 60 days.

Pfenex investors and others should note that we announce material information to the public about the Company through a variety of means, including our website (View Source), our investor relations website (View Source), press releases, SEC filings, public conference calls, corporate Twitter account (View Source), Facebook page (View Source), and LinkedIn page (View Source) in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our disclosure obligations under Regulation FD. We encourage our investors and others to monitor and review the information we make public in these locations as such information could be deemed to be material information. Please note that this list may be updated from time to time.

NantKwest to Present at Upcoming Investment and Healthcare Conferences

On March 13, 2018NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell-based therapeutics company, reported that the company will be presenting and conducting one-on-one meetings at a number of investment and healthcare conferences in the month of March and April 2018 (Press release, NantKwest, MAR 13, 2018, http://ir.nantkwest.com/phoenix.zhtml?c=254059&p=RssLanding&cat=news&id=2337947 [SID1234524736]). The presentations and one-on-one discussions will feature a science and business overview, along with a clinical update provided by company management.

Conference Details:
Event: Roth Capital 30th Annual Investment Conference
Date/Time: Tuesday, March 13, 2018, one-on-one meetings
Location: Laguna Niguel, CA

Event: Cowen & Company 38th Annual Healthcare Conference
Date/Time: Wednesday, March 14, 2018, one-on-one meetings
Location: Boston, MA

Event: Oppenheimer & Company 28th Annual Healthcare Conference
Date/Time: Tuesday, March 20, 2018, one-on-one meetings
Location: New York, NY

Event: Needham & Company 17th Annual Healthcare Conference
Date/Time: Wednesday, March 28, 2018, presentation at 12:45pm
Location: New York, NY

Event: Hanson Wade Innate Killer Summit
Date/Time: Thursday, March 29, 2018, presentation at 12:50pm
Location: New York, NY

Event: Jefferies IO Cell Therapy Investment Conference
Date/Time: Tuesday, April 3, 2018, presentation at 11:40am
Location: Boston, MA

Medtronic EVP & President Hooman Hakami to Speak at Oppenheimer Healthcare Conference

On March 13, 2018 Medtronic plc (NYSE:MDT), the global leader in medical technology, reported it will participate in the Oppenheimer 28th Annual Healthcare Conference on Tuesday, March 20, 2018, in New York City (Press release, Medtronic, MAR 13, 2018, View Source;p=RssLanding&cat=news&id=2337864 [SID1234524735]).

Hooman Hakami, executive vice president and group president of Medtronic’s Diabetes Group, will answer questions about the company beginning at 8:35 a.m. EDT (7:35 a.m. CDT).

A live audio webcast of the presentation will be available on March 20, 2018, by clicking on the Investor Events link at View Source An archive of the session will be available on the same webpage later in the day.

Roche Annual General Meeting 2018

On March 13, 2018 Roche (SIX: RO, ROG; OTCQX: RHHBY) reported that its shareholders approved all proposals of the Board of Directors at its ordinary Annual General Meeting (AGM) (Press release, Hoffmann-La Roche, MAR 13, 2018, View Source [SID1234524733]). The 880 attending shareholders, representing 86,42% of the total of 160,000,000 shares, approved the Management Report, the Financial Statements and the Consolidated Financial Statements for 2017.

Christoph Franz was confirmed as Chairman of the Board of Directors with 99,89% of the votes.

"2017 was a good year for Roche. The launch of Ocrevus for people with multiple sclerosis and the approval of Hemlibra for the treatment of people with haemophilia A were outstanding. In particular, we made significant progress in the areas of personalised healthcare and digitization. In this field, we have entered into important partnerships that complement our own expertise. I believe Roche is very well prepared for the future," said Christoph Franz, Chairman of Roche’s Board of Directors.

Shareholders also authorised the ratification of the Board of Directors’ actions and approved an increase in the gross dividend for the past financial year to 8.30 Swiss francs (gross) per share and non-voting equity security. This is the 31st consecutive dividend increase.

Shareholders endorsed the total amount of bonuses paid to the Corporate Executive Committee for 2017 with 99,62% of the votes, as well as the bonus paid to the Chairman of the Board of Directors for 2017, which was approved by 99,51% of the votes. They also approved the maximum total amount of future remuneration of the Board of Directors, which was confirmed by 99,62% of the votes, and the maximum total amount of future remuneration for the Corporate Executive Committee until the 2019 ordinary Annual General Meeting by 99,64% of the votes.

In addition to Christoph Franz, all other Board members who stood for re-election were confirmed for a term of one year:

André Hoffmann
Professor Sir John Bell
Julie Brown
Paul Bulcke
Anita Hauser
Professor Dr Richard P. Lifton
Dr Andreas Oeri
Bernard Poussot
Dr Severin Schwan
Dr Claudia Süssmuth Dyckerhoff
Peter R. Voser

The following Board members were elected to the Remuneration Committee:

Dr Christoph Franz
André Hoffmann
Professor Dr Richard P. Lifton
Bernard Poussot
Peter R. Voser

KPMG AG was elected as external auditor for the financial year 2018 and BDO AG was elected as independent voting proxy until the conclusion of the next regular AGM in 2019.

ERYTECH to Webcast Presentation at the Cowen and Company 38th Annual Healthcare Conference

On March 13, 2018 ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, reported that Chief Executive Officer, Gil Beyen, will present at the Cowen and Company 38th Annual Health Care Conference on Wednesday, March 14, 2018 at The Marriott Copley Place, in Boston, MA (Press release, ERYtech Pharma, MAR 13, 2018, View Source;p=RssLanding&cat=news&id=2337929 [SID1234524732]).

Conference Details:

Conference: Cowen and Company 38th Annual Health Care Conference
Date: March 14, 2018
Presentation Time: 9:20 AM EDT / 14:20 CET

A live webcast of the presentation will be available online from the investor relations page of the company’s corporate website at View Source and via the below link: http://wsw.com/webcast/cowen46/eryp/

Following, the live webcast, an archive of the presentation will be available on the company website for 30 days, under the "Investors" section at investors.erytech.com.